full screen background image


Agili-C™ cell-free implant for the treatment of degenerative and non-degenerative articular cartilage and osteochondral lesions

Agili-C™ is an off the shelf, cell-free implant that reproducibly regenerates hyaline cartilage and its underlying subchondral bone in a single-step procedure. Agili-C™ is CE marked for the treatment of focal articular cartilage and osteochondral defects.

Over 130 patients have been treated with Agili-C™ implants in multicenter studies.

Results to date show that this innovative and proprietary treatment leads to significant improvement in pain level, as well as reduction in related symptoms, with cartilage formation evidenced on MRI.

The Agili-C™ has also been shown to promote migration, adhesion, proliferation and differentiation of mesenchymal stem cells (MSCs) to simultaneously regenerate bone and cartilage.

Agili-C™ is a rigid bi-phasic, biodegradable implant. The bone phase of the implant is composed of calcium carbonate in aragonite crystalline form, a well-known biomaterial that enhances bone formation. The cartilage phase is a composite of modified aragonite and hyaluronic acid (HA). Following implantation of Agili-C™ several biological processes occur:

  • Adhesion, proliferation and differentiation of bone marrow MSCs

  • Bone remodelling by osteoblasts and osteoclasts

  • Invasion and ingrowth of chondrocytes from the periphery in parallel to the differentiation and proliferation of MSCs into chondrocytes

  • Implant biodegradation

The Agili-C™ implantation procedure is performed in an open approach using the unique Agili-Kit™ surgical toolset.

The product is not commercially available in the USA.